[Featured Stock] Medicox Highlights Diagnostic Device Domestic and European Distribution Contracts Amid Signs of COVID-19 Resurgence in Europe

[Asia Economy Reporter Minwoo Lee] Medicox's stock price is on the rise. As COVID-19 cases surged due to the spread of the Delta variant in Europe, where the pandemic had been subsiding, news that Medicox will supply COVID-19 diagnostic kits to domestic and all European regions has gained attention.

As of 9:52 AM on the 28th, Medicox's stock price recorded 1,430 KRW, up 8.75% compared to the previous day. The news that Medicox will exclusively supply diagnostic kits developed by Plexense, a company specializing in COVID-19 diagnostic kit R&D, amid signs of COVID-19 resurgence domestically and internationally, appears to have acted as a positive factor.

Recently, Medicox signed an exclusive distribution contract to sell and distribute COVID-19 diagnostic kits developed by Plexense throughout Korea and all European regions. Medicox plans to leverage its bio-business network to actively promote the product on all fronts.

Plexense has developed COVID-19 serological antibody diagnostic kits, saliva antigen diagnostic kits, and serological neutralizing antibody diagnostic kits by receiving technology transfers for COVID-19 antigen and neutralizing antibody from the Korea Research Institute of Bioscience and Biotechnology and the Osong Advanced Medical Industry Promotion Foundation under the Ministry of Health and Welfare, respectively.

Meanwhile, the COVID-19 'Delta' variant is rapidly spreading across Europe. The UK extended its COVID-19 lockdown by four weeks due to the spread of the Delta variant. In Denmark, a 'Delta Plus' variant, which is more transmissible than the Delta variant, has also been detected. Australia, which had relatively managed COVID-19 well, recently decided to lock down major cities such as Sydney and Darwin due to the spread of the Delta variant.

This content was produced with the assistance of AI translation services.